CASI Pharmaceuticals
CASI, we focus on building a pipeline through mutually beneficial business development transactions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $15.0m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (90 %) | 267 % | 99 % | 43 % | (21 %) | (16 %) | (56 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (760 %) | (107 %) | (106 %) | (18 %) | (57 %) | (127 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1114 %) | (319 %) | (121 %) | (95 %) | (80 %) | (138 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 236 % | 76 % | 48 % | 37 % | 29 % | 31 % | - |
Source: Company filings or news article, Equity research estimates
Related Content
CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products. The company primarily targets the Greater China market, leveraging its extensive regulatory and commercial expertise in China along with its global drug development capabilities. CASI serves a diverse range of clients, including healthcare providers, hospitals, and pharmaceutical distributors. The company operates in the biopharmaceutical sector, focusing on both commercially available and clinical-stage drug candidates. CASI's business model involves acquiring assets at various stages of development through in-licensing and acquisitions, which are then developed and commercialized to generate revenue. The company makes money through the sale of its pharmaceutical products and potential licensing agreements.
Keywords: biopharmaceutical, therapeutics, Greater China, regulatory expertise, commercial competencies, drug development, clinical-stage, in-licensing, acquisitions, NASDAQ-listed.
